Sign In
Buy LCA
$10.54
+0 (+0%)
At Close: May 24, 2024
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
04:30pm, Monday, 04'th May 2026
RESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene
Opus Genetics: Asymmetric Upside With LCA5 And BEST1
09:35pm, Sunday, 22'nd Feb 2026
Opus Genetics targets inherited retinal diseases with one-dose AAV gene augmentations. Its lead candidate is OPGx-LCA5, which is moving into Phase 3 enrollment. Interestingly, OPGx-LCA5's Phase 1/2 sh
EL SEGUNDO, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- With a mission to positively impact human health, climate change, constraints on natural resources and animal welfare, Beyond Meat, Inc. (NASDAQ:
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5 First participant enrolled in run-in period for p
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
07:00am, Tuesday, 30'th Sep 2025
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicities Lasting, durable responses obs
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
08:00am, Tuesday, 06'th May 2025
RESEARCH TRIANGLE PARK, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inher
Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutatio
First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is exp
Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
08:00am, Wednesday, 05'th Mar 2025
New Data from First Three Adult Patients in Phase 1/2 Trial with OPGx-LCA5 Showed that Subjective and Objective Signs of Efficacy Persisted for One Year New Data from First Three Adult Patients in Pha
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
07:30am, Tuesday, 18'th Feb 2025
First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025 New 12-month data on the first three adult OPGx-LCA5 patients to be p
EL SEGUNDO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- With a mission to positively impact human health, climate change, constraints on natural resources and animal welfare, Beyond Meat, Inc. (NASDA
Segway-Ninebot Goes Green with Electric KickScooters and More Sustainable Practices
04:57am, Monday, 03'rd Jul 2023
BEIJING, July 3, 2023 /PRNewswire/ — Segway-Ninebot, a global enterprise in the field of intelligent short-distance transportation and service robots, has received the world’s first Life Cycle Ass
Last Chance for Animals, Animal Liberation Wave Undercover Investigation Unveils More Atrocities in South Korean Dog Meat Trade
02:29pm, Sunday, 14'th Aug 2022
SEOUL, South Korea and LOS ANGELES, Aug. 14, 2022 /PRNewswire/ – A new, five-month undercover investigation by Los Angeles-based Last Chance for Animals (LCA) and Seoul-based Animal Liberation Wave
A recent study by The Energy and Resources Institute (TERI), a first-of-its-kind in India, comparing the most used beverage packaging substrates, sh...
